Cypherpunk Technologies earnings release, May 14, 2026

Cypherpunk Technologies Inc. (CYPH) · Form 8-K, Item 2.02 · Filed · SEC filing

Cypherpunk Technologies Reports First Quarter

2026 Financial Results

Cambridge,

MA – May 14, 2026 – Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the first quarter ended March 31, 2026.

"Since the start of 2026, Cypherpunk has advanced the mission to become a leading privacy technology company with a digital asset treasury strategy focused on Zcash by making our first privacy technology investment and increasing our treasury holdings to 314,185.70 ZEC,” said Douglas E. Onsi, President and CEO of Cypherpunk Technologies.

“At AACR 2026, our Leap Therapeutics subsidiary presented a new DKK1 biomarker assay developed to support the selection of patients likely to benefit from sirexatamab therapy, along with the positive outcomes from our DeFianCe colorectal cancer study generated in patients with high DKK1 levels. In addition, sirexatamab received Fast Track designation from the FDA in May 2026.”

“

Privacy-protecting assets and related technologies will be critical in the increasingly digital and AI driven world. Our $5 million investment in Zcash Open

Development Labs (ZODL), the core developers of the Zcash Network and Zodl, the leading Zcash wallet, reflects our commitment to supporting the Zcash ecosystem and to building innovative companies that make the promise of private digital money a reality,” said Will McEvoy,

Chief Investment Officer of Cypherpunk.

Cypherpunk Highlights:

Leap Therapeutics Subsidiary Highlights:

Selected First Quarter 2026 Financial Results

Net loss was $77.2 million for the first quarter 2026, compared to

$15.4 million for the first quarter of 2025. The increase was primarily due to unrealized losses on the fair value of the Company's ZEC treasury holdings which are marked to market at the end of each period. During the first quarter of 2026, the price of ZEC declined from

$508.09 to $240.47.

Research and development expenses were $0.2 million for the three months ended March 31, 2026, compared to $12.9 million for the same period in 2025. The decrease for the three months ended March 31,

2026 was primarily due to a decrease in clinical trial costs and manufacturing costs due to the completion of our clinical trials.

General and administrative expenses were $4.7 million for the three months ended March 31, 2026, compared to $3.0 million for the same period in 2025. The increase for the three months ended March 31,

2026 was primarily due to an increase in stock-based compensation expense due to RSUs granted to employees and directors.

During the three months ended March 31, 2026, the Company recorded a $77.6 million unrealized loss on the change in fair value of the Company’s ZEC treasury holdings as the price of ZEC declined during the first quarter of 2026 from $508.09 to $240.47.

Cash and cash equivalents totaled $6.7 million on March 31, 2026, and ZEC treasury holdings, categorized as digital asset receivable, totaled $73.8 million based on the ZEC price of $240.47 on March 31,

2026.

About Cypherpunk

Cypherpunk

Technologies is a privacy technology company. The Company's mission is to advance technologies that guarantee privacy for humans on the internet. Cypherpunk pursues this mission through two primary strategies: accumulating Zcash (ZEC); and investing in, acquiring, and building technologies that push the frontier of privacy forward. Additionally, through its subsidiary Leap Therapeutics, the Company is developing novel therapies for patients with cancer, continuing the development of sirexatamab and FL-501. For more information about the Company, visit our websites at http://www.cypherpunk.com and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov.

About Winklevoss Capital

Winklevoss Capital is an investment firm founded in 2012 by Cameron and Tyler Winklevoss that invests in frontier technologies.

Financial statements

Income Statement

Consolidated Statements of Operations (in thousands, except share and per share amounts)

(Unaudited) – Three Months Ended March 31 – 2026(Unaudited) – Three Months Ended March 31 – 2025
Operating expenses:Research and development16112,911
Operating expenses:General and administrative4,6563,006
Operating expenses:Total operating expenses4,81715,917
Operating expenses:Loss from operations-4,817-15,917
Operating expenses:Interest income95437
Operating expenses:Interest expense-7-6
Operating expenses:Australian research and development incentives55
Operating expenses:Change in fair value of embedded derivative-77,555
Operating expenses:Foreign currency loss-4
Operating expenses:Loss before income taxes-82,284-15,435
Operating expenses:Benefit from income taxes5,118
Operating expenses:Net loss attributable to common stockholders-77,166-15,435
Net loss per shareBasic and diluted-0.46-0.37
Weighted average common shares outstandingBasic and diluted168,103,53541,268,894

Balance Sheet

December 31, — Cypherpunk Technologies Inc. Consolidated Balance Sheets (in thousands, except share and per share amounts)

March 31, – 2026 – (Unaudited)December 31, – 2025
Current assets:Cash and cash equivalents6,68914,035
Current assets:Digital assets receivable73,849147,404
Current assets:Research and development incentive receivable616602
Current assets:Prepaid expenses and other current assets76840
Current assets:Total current assets81,922162,081
Current assets:Right of use assets, net3838
Current assets:Deferred costs385401
Current assets:Deposits33662
Current assets:Other investment5,000
Current assets:Total assets87,378163,182
Current liabilities:Accounts payable5161,981
Current liabilities:Accrued expenses1,9662,067
Current liabilities:Income tax payable483472
Current liabilities:Lease liability3838
Current liabilities:Total current liabilities3,0034,558
Non-current liabilities:Deferred tax liability5,118
Non-current liabilities:Total liabilities3,0039,676
Stockholders' equity:Common stock, $0.001 par value; 490,000,000 shares authorized; 93,927,528 and 83,851,051 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively9484
Stockholders' equity:Stock subscription receivable-150
Stockholders' equity:Additional paid-in capital624,082616,216
Stockholders' equity:Accumulated other comprehensive loss-86-95
Stockholders' equity:Accumulated deficit-539,715-462,549
Stockholders' equity:Total stockholders’ equity84,375153,506
Stockholders' equity:Total liabilities and stockholders' equity87,378163,182

Cash Flow

(in thousands)

(Unaudited) – Three Months Ended March 31, – 2026(Unaudited) – Three Months Ended March 31, – 2025
Cash used in operating activities-3,430-14,480
Cash used in investing activities-9,000
Cash provided by (used in) financing activities5,075-61
Effect of exchange rate changes on cash and cash equivalents95
Net decrease in cash and cash equivalents-7,346-14,536
Cash and cash equivalents at beginning of period14,03547,249
Cash and cash equivalents at end of period6,68932,713
Full release

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe,"

"estimate," "forecast," "goal," "project," and other words of similar meaning. Forward-looking statements address various matters including statements relating to the value of the Company’s ZEC holdings, the investment in ZODL, or digital assets held or to be held by the Company, the expected future market, price, and liquidity of ZEC or other digital assets the

Company acquires, the macro and political conditions surrounding Zcash or digital assets, the Company’s plan for value creation and strategic advantages, market size and growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business strategies, technological and market trends, and future financial condition and performance. Risks and uncertainties of the digital asset treasury strategy include, among others: (a) risks relating to the Company’s operations and business, including the highly volatile nature of the price of ZEC; (b) the risk that material changes in the price of ZEC, such as decreases in price, will result in significant changes to the Company’s financial statements, such as unrealized losses on fair value of ZEC holdings and net loss; (c) the risk that the price of the Company’s Common Stock may be highly correlated to the price of ZEC; (d) the risk that the Company will fail to realize the anticipated benefits of the ZEC digital asset treasury strategy... (truncated)s affiliates for trading and custody services; (f) changes in business, market, financial, political and regulatory conditions; (g) risks related to increased competition in the industries in which the Company does and will operate; (h) risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; (i) risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and (j) the ability to comply with the continued listing requirements of the Nasdaq Capital Market.

With respect to our biotechnology operations, important factors that could cause actual results to differ materially from our plans, estimates or expectations could include, but are not limited to:

(i) our ability and plan to develop and commercialize sirexatamab; (ii) our estimates regarding our capital requirements and our ability to raise additional financing to support continued development; (iii) the success of other competing therapies that may become available; (iv) the manufacturing capacity for sirexatmab; and (v) our ability to maintain and protect our intellectual property rights.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The Company may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk

Factors" in the Company’s most recent Annual Report on Form 10-K filed with the SEC, or as may be included in other reports or information we file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

CONTACT:

Douglas E. Onsi

President & Chief Executive Officer

Cypherpunk Technologies Inc.

617-714-0360

For Investors:

Matthew DeYoung

Investor Relations

Argot Partners

212-600-1902 leap@argotpartners.com

For Media:

Jacqueline Ortiz Ramsey

It Factor Strategies

954-294-3249 jacqueline@itfactorstrategies.com

Cypherpunk Technologies

Inc.

Consolidated Statements of Operations

(in thousands, except share and per share amounts)

Cypherpunk Technologies

Inc.

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

Cypherpunk Technologies

Inc.

Condensed Consolidated

Statements of Cash Flows

(in thousands)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Cypherpunk Technologies earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.